#Germany #Düsseldorf #Fapon #MEDICA 2025 #Alzheimer’s test

Fapon's Revolutionary Participation at MEDICA 2025

From November 17 to 20, 2025, Fapon, a global leader in life sciences, will showcase its pioneering advancements in diagnostics at MEDICA 2025 in Düsseldorf, Germany. The event serves as a platform for innovation, where Fapon will demonstrate the integration of artificial intelligence (AI) in research and development for in vitro diagnostics (IVD).

One of the standout highlights will be Fapon's advanced blood analysis solutions targeting Alzheimer’s disease (AD). By utilizing a unique AI-driven research and development model combined with a closed-loop experimental cycle, Fapon significantly enhances the efficiency of biomarker discovery and diagnostic solution development.

The Alzheimer’s testing initiative exemplifies the organization’s commitment to providing diagnostic manufacturers with comprehensive raw materials and bulk reagents. These materials encompass crucial biomarkers, including p-tau 217, p-tau 181, beta-amyloid 40, beta-amyloid 42, GFAP, NfL, and APOE4. These innovative products exhibit high sensitivity and specificity while maintaining an excellent correlation with established clinical diagnostic tests, leading to more accurate and reliable AD assays.

In addition to its leading-edge Alzheimer’s solutions, Fapon will introduce its integrated IVD offerings, which comprise raw materials, reagent services, and open system instruments. Among these innovations is a comprehensive chemiluminescence solution that utilizes high-performance raw materials and features an extensive panel of over 70 internally developed assays. The adaptable Shine i-Series CLIA analyzers are designed to meet a wide range of analytical needs, from low to ultra-high throughput scenarios.

Moreover, the fully automated clinical chemistry and immunoassay system, Shine mT8000, provides complete workflow automation in a compact format, requiring only 5 m² of space. This design not only maximizes operational efficiency but also enhances accessibility for laboratories with limited space.

Fapon’s portfolio also includes high-performance raw materials for IVDs, such as recombinant raw materials for quality control and calibration of vital disease markers (FR, HbA1c, HIV, HCV, TP, HBV, and ToRCH), animal-free IgG blockers, and LAMP solutions for rapid molecular diagnostics.

Currently, Fapon’s products and services reach over 70 countries and regions, supported by more than 2,500 global partners. The organization aims to elevate healthcare worldwide through technology transfer and support for localized manufacturing.

About Fapon

Fapon is redefining the paradigm of research and development in diagnostics and therapies with its pioneering model of AI plus a closed-loop IVD experimental cycle. This innovative approach accelerates the discovery and translation of new biomarkers and therapeutic targets. With a fully integrated business structure that fuses AI-driven innovation discoveries, comprehensive diagnostic solutions, and novel therapies, Fapon is committed to expediting the advancement of precision medicine across the entire health management spectrum throughout the human lifecycle.

Stay connected with Fapon on LinkedIn or visit our website at Fapon.